Trials / Completed
CompletedNCT00358527
Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)
A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects With Symptomatic Seasonal Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 401 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will hope to show that by relieving the participant's nasal symptoms of seasonal allergies using mometasone furoate nasal spray, the participant will obtain a better quality of night-time sleep, which in turn, causes less daytime sleepiness so that he/she can function productively during the day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone Furoate Nasal Spray (MFNS) | MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days. |
| OTHER | Placebo | Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2006-10-01
- Completion
- 2006-11-01
- First posted
- 2006-08-01
- Last updated
- 2022-02-08
- Results posted
- 2010-03-11
Source: ClinicalTrials.gov record NCT00358527. Inclusion in this directory is not an endorsement.